PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
A Novel Patient-specific Protein Expression-based Algorithmic Model for Immune Checkpoint Inhibition Therapy Response Prediction in a Pan-cancer Cohort
Version 1
: Received: 8 August 2019 / Approved: 11 August 2019 / Online: 11 August 2019 (14:51:14 CEST)
How to cite:
Bamodu, O.A.; Cheng, W.; Bamodu, O.; Lee, W.; Lee, K.; Wang, L.; Chao, T.; Yeh, C. A Novel Patient-specific Protein Expression-based Algorithmic Model for Immune Checkpoint Inhibition Therapy Response Prediction in a Pan-cancer Cohort. Preprints2019, 2019080131. https://doi.org/10.20944/preprints201908.0131.v1
Bamodu, O.A.; Cheng, W.; Bamodu, O.; Lee, W.; Lee, K.; Wang, L.; Chao, T.; Yeh, C. A Novel Patient-specific Protein Expression-based Algorithmic Model for Immune Checkpoint Inhibition Therapy Response Prediction in a Pan-cancer Cohort. Preprints 2019, 2019080131. https://doi.org/10.20944/preprints201908.0131.v1
Bamodu, O.A.; Cheng, W.; Bamodu, O.; Lee, W.; Lee, K.; Wang, L.; Chao, T.; Yeh, C. A Novel Patient-specific Protein Expression-based Algorithmic Model for Immune Checkpoint Inhibition Therapy Response Prediction in a Pan-cancer Cohort. Preprints2019, 2019080131. https://doi.org/10.20944/preprints201908.0131.v1
APA Style
Bamodu, O.A., Cheng, W., Bamodu, O., Lee, W., Lee, K., Wang, L., Chao, T., & Yeh, C. (2019). A Novel Patient-specific Protein Expression-based Algorithmic Model for Immune Checkpoint Inhibition Therapy Response Prediction in a Pan-cancer Cohort. Preprints. https://doi.org/10.20944/preprints201908.0131.v1
Chicago/Turabian Style
Bamodu, O.A., Tsu-Yi Chao and Chi-Tai Yeh. 2019 "A Novel Patient-specific Protein Expression-based Algorithmic Model for Immune Checkpoint Inhibition Therapy Response Prediction in a Pan-cancer Cohort" Preprints. https://doi.org/10.20944/preprints201908.0131.v1
Abstract
Background: Accurate prediction of patients’ response to therapy is clinically indispensable, howbeit challenging. With increased understanding of the human genome and malignancies, there is the renaissance of in silico pharmacogenomics with renewed interest in drug response predictability based on gene-drug interaction. Objective: Evidence-based transcript-proteome profiling is essential for synthesizing clinically applicable algorithms for predicting response to anticancer therapy, including immune checkpoint blockade (ICBT); thus, saving physicians’ time, reducing polypharmacy, and curtailing unnecessary treatment expense. In this study, we tested and validated the hypothesis that a selected proteomic signature in ICBT-naïve patients is sufficient for the prediction of response to ICBT. Methods: Using a multimodal approach consisting of computational pharmacogenomics, transcript-proteome analytics, mathematical modeling, and machine learning systems; we delineated therapy-sensitivity and stratified patients into graduated response groups based on their proteomic profile. Protein expression levels in our cohort tissue specimens were evaluated based on T cell- and non-T cell- inflamed phenotypes by immunohistochemistry. Results: We established β-catenin, PDL1, CD3 and CD8 expression-based ICBT response model. Statistical regression models validated the predictive association between our predefined algorithms and therapeutic outcome. Interestingly, our 4-gene prediction classifier was constitutively independent of tumor tissue origin, correctly stratified patients into high-, low-, and non- responders pre-treatment, with high prediction accuracy, and exhibited good association with patients’ performance status and prognosis (p < 0.01). Conclusion: Our findings demonstrate the possibility of accurate proteomics based ICBT response prediction and provide a putative basis for drug response prediction based on selective proteome profile in untreated cancer patients.
Keywords
pharmacogenomics; immune checkpoint blockade; immunotherapy; drug response prediction; algorithm; mathematical model; precision medicine; personalized medicine
Subject
Biology and Life Sciences, Anatomy and Physiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
